Five year update of ECHELON-1 for classical Hodgkin lymphoma

Bookmark and Share
This content is restricted to members who are registered with ecancer as a healthcare professional.
Please login or register for free to confirm your details.
Published: 8 Dec 2020
Views: 721
Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil

Dr Otavio Baiocchi speaks to ecancer about brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical Hodgkin lymphoma.

This is a 5-year update of the ECHELON-1 study, presented at the ASH 2020 meeting.

Dr Baiocchi initially gives the updates from the ECHELON-1 study and explains what we have learnt so far about the use of brentuximab vedotin in treating stage III/IV classical Hodgkin Lymphoma.

He then covers the methodology used in this study and the end-points evaluated after 3 years and then after 5 years.

He concludes by talking about the future of this study in terms of clinical care and further investigation on more viable treatment options for Hodgkin lymphoma.

This programme has been supported by an unrestricted educational grant from Takeda.